Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-16 am EDT			5-day change	1st Jan Change
2,519.50 ^JPY	-1.04%		-0.36%	-24.75%

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
Jun. 03	Leica Biosystems, AstraZeneca , and Daiichi Sankyo Expand Collaboration to Scale Precision Medicine and Develop AI -Powered Diagnostics	CI

Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings

Published on 04/24/2026 at 01:04 am EDT

Dow Jones

DAIICHI SANKYO COMPANY, LIMITED

-1.04%

By Jason Chau

Shares of Daiichi Sankyo tumbled after the Japanese drugmaker delayed the release of its earnings results.

Daiichi Sankyo's stock declined nearly 11% to 2,497.50 yen, equivalent to $15.64, in Friday morning's trading session in Tokyo, marking its steepest intraday decline since August 2024.

The pharmaceutical company said it will report the results for the fiscal year ended March 2026 on May 11, instead of the originally scheduled April 27.

It attributed the delay to a review of its supply plans for its oncology portfolio and development pipeline, and further deliberations to estimate the loss provisions related to contract manufacturing.

Daiichi Sankyo said it would also release its five-year business plan for 2026-2030 on May 11, brought forward from May 19.

The delay in the earnings release comes amid rapid changes in the drugmaker's business environment as it pivots toward innovative drug discovery, particularly in the field of oncology. Earlier this month, it agreed to sell its over-the-counter drug business to Japanese beverage giant Suntory Holdings for about $1.55 billion.

Daiichi Sankyo shares are down nearly 26% so far this year.

Write to Jason Chau at jason.chau@wsj.com

(END) Dow Jones Newswires

04-24-26 0103ET

Latest news about Daiichi Sankyo Company, Limited

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
Jun. 03	Leica Biosystems, AstraZeneca , and Daiichi Sankyo Expand Collaboration to Scale Precision Medicine and Develop AI -Powered Diagnostics	CI
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE
May. 28	Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO	CI
May. 26	AstraZeneca says Datroway approved in US for 1L triple-negative BC	RE
May. 22	FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress	MT
May. 22	AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator	DJ
May. 22	AstraZeneca and Daiichi cancer drugs clear regulatory hurdles	AN
May. 22	AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer	MT
May. 22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Wins US FDA Approval	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S	CI
May. 22	AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2-Positive Solid Tumors	MT
May. 22	AstraZeneca, Daiichi Sankyo Win EU Panel's Recommendation for Metastatic Solid Tumors Therapy	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Enhertu's Recommendation for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	CI
May. 22	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Company Profile

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

More about the company